Post Approval Life Cycle Management of Variations for Generic Drugs in Brazil

Authors

  • Achin jain iMEDGLOBAL Private Limited, Bangalore, Karnataka, India
  • Neenu Ganesh JSS College of Pharmacy, Jagadguru Sri Shivarathreeswara University, Mysore, Karnataka, India

DOI:

https://doi.org/10.37591/rrjodfdp.v4i3.21

Abstract

Changes or variations in respect of any information concerning the registered or approved drug products, including information on the formulation of the registered/listed goods or other aspects of their manufacture, and the labeling of the goods, shall forthwith be notified to the agency and the change or variation shall not be implemented until approved by the agency. Changes occurs to have business continuity, if any quality problem arises, to maintain the economy, process improvisation, alternate addition of sources or exclusions. The applicants of registered generics who intend to make post-approval changes should follow the guidance or regulation in accordance to the ANVISA. Most of the regulations classify the changes for drug substances and drug products. The objective of this paper is to give insight and better understanding of the classification of changes in Brazil.

 Keywords: change, variation, Generics, ANVISA

Cite this Article

Jain A, Ganesh N. Post Approval Life Cycle Management of Variations for Generic Drugs in Brazil. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2017; 4(3): 37–42p.

Downloads

Published

2018-03-22

Issue

Vol. 4 No. 3 (2017)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.